Revolutionary wound dressing could halve healing time by targeting inflammation

A new wound dressing designed to accelerate healing could soon reach hospitals and clinics. Developed by ResCure GmbH, the treatment targets chronic inflammation and has shown promising results in tests. The company, a spin-off from Dresden's Leibniz Institute of Polymer Research, is now pushing for regulatory approval and large-scale production.

The dressing works by neutralising inflammatory molecules at the injury site. A specialised polymer captures and deactivates pro-inflammatory signals, cutting healing time by up to 50% in lab trials. Applied directly to wounds, it aims to break the cycle of persistent inflammation that delays recovery.

ResCure GmbH has secured patents and trademark rights from the Leibniz Institute of Polymer Research Dresden. The European Union is backing the project through funding from the Saxon Development Bank. This support helps bridge the gap between research and commercial use. Under Dr. Uwe Freudenberg's leadership, the company is now preparing for CE certification—a legal requirement for medical devices in Europe. Once approved, production will scale up to ensure rapid availability. The goal is to launch the dressing by 2027, with plans to later adapt the technology for other chronic inflammatory conditions.

The dressing's approval would offer a new option for patients with slow-healing wounds. If successful, it could also reduce costs for healthcare systems by shortening treatment times. ResCure GmbH expects to begin commercial distribution within the next three years.